Form 4: Xeris Biopharma Legal Officer Sells Shares

Xeris Biopharma Holdings, Inc.'s Chief Legal Officer, Beth Hecht, sold 16,667 shares of common stock for a weighted average price of $7.0067 per share under a Rule 10b5-1 trading plan.

Summary

• Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., sold 16,667 shares of common stock.
• The transaction occurred on December 1, 2025, at a weighted average price of $7.0067 per share.
• The shares were sold in multiple transactions within a price range of $6.930 to $7.120.
• The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following the transaction, Beth Hecht directly beneficially owns 1,320,176 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine insider sale under a pre-arranged 10b5-1 plan, which typically does not indicate a significant positive or negative sentiment about the company's immediate prospects.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than an immediate reaction to new information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by investors as it reduces insider ownership.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4.

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Industry Context

Insider sales are common across all industries, including biopharma. A sale under a 10b5-1 plan is generally viewed as less impactful than an unscheduled sale, as it suggests a pre-determined financial planning decision rather than a reaction to recent company news.

Comparison to Industry Standards

• Insider trading plans under Rule 10b5-1 are a standard practice for executives across various industries, including biopharma, to sell shares systematically while avoiding accusations of trading on material non-public information. Companies like Pfizer, Johnson & Johnson, and Merck often see similar filings from their executives.
• The volume of shares sold (16,667) represents a small fraction of the total shares beneficially owned (1,320,176), which is typical for routine diversification or liquidity events rather than a significant loss of confidence.

Stakeholder Impact

• Shareholders: May interpret the sale as a minor reduction in insider alignment, though mitigated by the 10b5-1 plan. The impact is likely minimal given the routine nature.

Key Dates

Recommendation

The filing details a routine insider sale under a Rule 10b5-1 plan, which is a common practice for executives to manage personal finances and diversify holdings. It does not provide new material information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on existing company fundamentals and market outlook.

Keywords

Xeris Biopharma Holdings, XERS, Insider Sale, Form 4, Beth Hecht, Stock Transaction, Rule 10b5-1, Biopharma, Legal Officer